Found 1985 with Last Name = 'fleming' and Initial = 'pe' TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 1.20nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 1.20nMAssay Description:In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shif...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 1.20nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HE...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 5.10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 5.10nMAssay Description:In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shif...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 5.10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HE...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 7.90nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 7.90nMAssay Description:In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shif...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 7.90nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HE...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HE...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HEPES...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HEPES...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HE...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HEPES...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HE...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
